Почетна › Беркитов лимфом › Тексас › Houston
Клинички испитувања за Беркитов лимфом во Houston, TX
Една студија за Беркитов лимфом бара учесници на локација во или блиску до Houston. Отворете ја за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Се регрутираФаза 3
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Се регрутираФаза 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Се регрутираФаза 3
- Houston Methodist Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Се регрутираНабљудувачка студија
- Texas Children's Hospital, Houston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Се регрутираФаза 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Се регрутираФаза 3
- The University of Texas MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Се регрутираФаза 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Се регрутираФаза 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Се регрутираФаза 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Се регрутираФаза 1/2
- Research Site, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Се регрутираФаза 2
- Baylor Texas Children's Hospital, Houston
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Се регрутираФаза 2
- M D Anderson Cancer Center, Houston
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Се регрутираФаза 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Се регрутираФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Се регрутираФаза 1/2
- M D Anderson Cancer Center, Houston
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Се регрутираФаза 1/2
- Research Site, Houston
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
Се регрутираФаза 2
- M D Anderson Cancer Center, Houston
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Се регрутираФаза 1
- University of Texas MD Anderson Cancer Center, Houston
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Се регрутираФаза 1/2
- MD Anderson Cancer Center, Houston
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Се регрутираФаза 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Се регрутираФаза 1
- MD Anderson Cancer Center, Houston
Испитувања за Беркитов лимфом во други градови
- Philadelphia, PA16 студии
- Milwaukee, WI16 студии
- Chicago, IL15 студии
- Cincinnati, OH13 студии
- New York City, NY13 студии
- Atlanta, GA12 студии
- Aurora, CO11 студии
- Seattle, WA11 студии
- Durham, NC10 студии
- Boston, MA10 студии
- Kansas City, MO10 студии
- Los Angeles, CA10 студии
Други студии во Houston
- Рак на бели дробови со не-мали клетки145 студии
- Рак на дојка126 студии
- Рак (сите типови)121 студија
- Метастатски карцином104 студии
- Колоректален карцином102 студии
- Карцином на јајниците89 студии
- Акутна миелоидна леукемија85 студии
- Рак на бели дробови78 студии
- Рак на простата76 студии
- Рак на ендометриумот68 студии
- Карцином на панкреасот61 студија
- Меланом59 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.